Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATARTIC: Capecitabine plus Temozolomide Chemoradiotherapy in LARC
2024-513931-26-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and temozolomide in rectal cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathologic complete response (pCR). Planned start Aug 2024; status: authorised.
02
Drugs
capecitabinetemozolomide
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-513931-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513931-26-00.